First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction

Ilana Chafetz, Ido Kuhnreich, Marei Sammar, Yossi Tal, Yair Gibor, Hamutal Meiri, Howard Cuckle, Myles Wolf

Research output: Contribution to journalArticlepeer-review

147 Scopus citations

Abstract

OBJECTIVE: The purpose of this study was to evaluate first-trimester serum placental protein 13 (PP13) as a screening test for preeclampsia and intrauterine growth restriction (IUGR).

STUDY DESIGN: We performed a prospective, nested case-control study in the Massachusetts General Hospital Obstetric Maternal Study. PP13 was measured by solid-phase sandwich enzyme-linked immunosorbent assay in serum samples that were collected at the first prenatal visit (9-12 weeks of gestation) from women who subsequently experienced preeclampsia (n = 47), IUGR (n = 42), or preterm delivery (n = 46). Women with uncomplicated term deliveries served as control subjects (n = 290) and were matched to cases by gestational age when serum was collected and for the duration of specimen storage.

RESULTS: The median first-trimester PP13 level was 132.5 pg/mL in the control subjects. Median PP13 levels were significantly lower among women who had preeclampsia (27.2 pg/mL; P < .001), IUGR (86.6 pg/mL; P < .001), and preterm delivery (84.9 pg/mL; P = .007). When PP13 was expressed as multiples of the gestational age-specific medians among the control subjects, the multiples of the medians were 0.2 for preeclampsia, 0.6 for IUGR, and 0.6 for preterm delivery (P < .001 for each disorder compared with control subjects). Receiver operating characteristic analysis yielded areas under the curve of 0.91, 0.65, and 0.60 for preeclampsia, IUGR, and preterm delivery, respectively. At a 90% specificity rate, the corresponding sensitivities were 79%, 33%, and 28%, respectively.

CONCLUSION: The screening of maternal PP13 levels in the first trimester is a promising diagnostic tool for the prediction of preeclampsia with high sensitivity and specificity.

Original languageEnglish (US)
Pages (from-to)35.e1-7
JournalAmerican journal of obstetrics and gynecology
Volume197
Issue number1
DOIs
StatePublished - Jul 2007

Keywords

  • Adult
  • Case-Control Studies
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Fetal Growth Retardation/blood
  • Galectins/biosynthesis
  • Gestational Age
  • Humans
  • Obstetric Labor, Premature
  • Placenta/metabolism
  • Pre-Eclampsia/blood
  • Predictive Value of Tests
  • Pregnancy
  • Pregnancy Proteins/biosynthesis
  • Pregnancy Trimester, First
  • Prospective Studies
  • Sensitivity and Specificity

PubMed: MeSH publication types

  • Clinical Trial
  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction'. Together they form a unique fingerprint.

Cite this